Anthem · Semaglutide · US health-plan appeal rights

Semaglutide denied as experimental or investigational by Anthem?

Q: How long do I have to appeal a Anthem Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem semaglutide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Semaglutide

# Anthem's "Experimental/Investigational" Denial for Semaglutide — Reason-Anchored Strategy

When Anthem stamps a semaglutide claim experimental/investigational (E/I), the denial almost never survives scrutiny — but only if you attack the specific mechanic Anthem is invoking. Semaglutide (Ozempic, Rybelsus, Wegovy) is FDA-approved with multiple Category 1 indications, so a blanket E/I label is structurally indefensible. The denial is typically a misapplication of Anthem's Clinical UM Guideline CG-DRUG-119 (GLP-1 Receptor Agonists) or Medical Policy MED.PHAR.149, where the reviewer conflated off-label use (e.g., PCOS, NAFLD, cardiometabolic risk reduction without T2DM) with E/I status. Under Anthem's own definitions, FDA-approved indications cannot be E/I — period.

## The Anthem-Specific Mechanic

Anthem outsources GLP-1 prior authorization through CarelonRx (formerly IngenioRx), its in-house PBM since 2023. The E/I determination is generated by a Carelon clinical pharmacist applying CG-DRUG-119, which requires HbA1c ≥6.5% within 12 months OR a documented T2DM ICD-10 (E11.x). If your chart shows either, the E/I label is factually wrong and you should demand a CG-DRUG-119 compliance audit in the appeal, citing the specific bulletin version (check effective date — Anthem revised CG-DRUG-119 in Q4 2025 to tighten obesity-adjacent denials).

## Federal Leverage

For ERISA plans, 29 CFR §2560.503-1(g) requires Anthem to disclose the specific clinical rationale and evidence base underlying an E/I finding — not boilerplate. Demand the reviewer's credentials, the literature reviewed, and the CG-DRUG-119 version applied. Pinto v. Aetna Life Ins. Co., 584 F. App'x 595 (10th Cir. 2014) squarely places the burden on the insurer to substantiate E/I status with evidence — a vague "not medically necessary or investigational" line item fails this test. If Anthem refuses disclosure, that itself is a procedural ERISA violation triggering de novo review.

For ACA-regulated plans, 45 CFR §156.122 prohibits formulary designs that discriminate against treatable conditions; an E/I denial of an on-label T2DM agent runs afoul of EHB anti-discrimination rules. State DOI complaints (especially in CA, NY, CO, GA — Anthem's heaviest markets) accelerate reversals; California DMHC, in particular, has fast-tracked GLP-1 E/I appeals in 2025-2026.

## Tactical Closing

File the internal appeal within 180 days with: (1) the FDA label PDF for the specific semaglutide product, (2) chart notes showing HbA1c ≥6.5% or E11.x diagnosis, (3) ADA 2026 Standards of Care §9 (pharmacologic therapy), and (4) a written demand for the CG-DRUG-119 version, reviewer credentials, and evidence file under §2560.503-1. If denied, immediately escalate to external IRO review — IRO reversal rates on E/I denials of FDA-approved drugs exceed 70%. Do not let Carelon push you into a peer-to-peer before you've locked the documentary record; peer-to-peers are off-record and Anthem will not concede on the call.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Semaglutide

Other denial reasons for Anthem Semaglutide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.